Drug Trial Radar · NCT05026866
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Last checked: Nov 20, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,996
Planned (sponsor's estimate)
Start
Aug 27, 2021
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Aug 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks. Approximately 800 additional participants will be enrolled in the 12-month Addendum 7 to assess safety of a different titration regimen.
Conditions
- Alzheimer Disease
Interventions
DonanemabDrug
Administered intravenously
PlaceboDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR) in the Primary Study Population (Baseline CDR-Global Score [GS 0])Time frame: Estimated up to Week 332
Locations
216 sites in 3 countries. Site status is shown where the registry gives one.
Parkway Medical Center
Birmingham, Alabama
Alabama Psychiatry - Birmingham - Brookwood Medical Center Drive
Homewood, Alabama
Rehabilitation & Neurological Services
Huntsville, Alabama
Care Access - 801 South Power Road, Mesa
Mesa, Arizona
Banner Alzheimer's Institute
Phoenix, Arizona
Banner Alzheimer's Institute Tucson
Tucson, Arizona
Center for Neurosciences
Tucson, Arizona
Care Access - Berkeley
Berkeley, California
Care Access - Beverly Hills
Beverly Hills, California
Velocity Clinical Research, Chula Vista
Chula Vista, California
Valley Clinical Trials, Inc.
Covina, California
Neurology Center of North Orange County
Fullerton, California
Care Access - Gilroy
Gilroy, California
Marvel Clinical Research
Huntington Beach, California
Care Access Research - Huntington Beach
Huntington Beach, California
Irvine Clinical Research
Irvine, California
Option Care - Irvine
Irvine, California
Kaizen Brain Center
La Jolla, California
Velocity Clinical Research, San Diego
La Mesa, California
Pacific Research Network
Lemon Grove, California
Healthy Brain Clinic
Long Beach, California
Neurovations
Napa, California
Care Access - Newport Beach
Newport Beach, California
Valley Clinical Trials, Inc.
Northridge, California
Inland Psychiatric Medical Group
Redlands, California
Anderson Clinical Research
Redlands, California
Artemis Institute for Clinical Research
Riverside, California
Option Care - Riverside
Riverside, California
Clinical Trials Research
Sacramento, California
Artemis Institute for Clinical Research
San Diego, California
Ray Dolby Brain Health Center
San Francisco, California
Care Access - Los Gatos
San Jose, California
Syrentis Clinical Research
Santa Ana, California
Care Access - Santa Clarita
Santa Clarita, California
Option Care - Los Angeles South
Santa Fe Springs, California
Providence Medical Foundation
Santa Rosa, California
Mazur, Statner, Dutta, Nathan, PC
Thousand Oaks, California
Tilda Research
Tustin, California
Velocity Clinical Research, Panorama City
Van Nuys, California
Infectious Disease Doctors Medical Group, APC
Walnut Creek, California
Showing 40 of 216 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.